Caffeic acid ameliorates colitis in association with increased Akkermansia population in the gut microbiota of mice

Oncotarget

Volumn 7, Issue 22, 2016, Pages 31790-31799

  Zhang, Zhan ^a   Wu, Xinyue ^a   Cao, Shuyuan ^a   Wang, Li ^a   Wang, Di ^a   Yang, Hui ^a   Feng, Yiming ^a   Wang, Shoulin ^b   Li, Lei ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Medical University   (China)

Author keywords

Caffeic acid; Dextran sulfate sodium; Fecal microbiota; Immune response; Immunity; Immunology and Microbiology Section; NF B pathway; Ulcerative colitis

Indexed keywords

CAFFEIC ACID; GAMMA INTERFERON; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; AUTACOID; CAFFEIC ACID DERIVATIVE; CYTOKINE; DEXTRAN SULFATE;

AKKERMANSIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIUM; CD177+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DIET SUPPLEMENTATION; FECES MICROFLORA; FEMALE; LYMPHOCYTIC INFILTRATION; MICROBIAL DIVERSITY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPECIES RICHNESS; T LYMPHOCYTE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; CLASSIFICATION; COLON; DISEASE MODEL; DRUG EFFECTS; FECES; GROWTH, DEVELOPMENT AND AGING; INTESTINE FLORA; MACROPHAGE; METABOLISM; MICROBIOLOGY; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; TIME FACTOR; VERRUCOMICROBIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CAFFEIC ACIDS; COLITIS; COLON; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; INFLAMMATION MEDIATORS; MACROPHAGES; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION; NEUTROPHILS; T-LYMPHOCYTES; TIME FACTORS; VERRUCOMICROBIA;

EID: 84973541347     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9306     Document Type: Article

References (40)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347:417-429.
2. Maloy KJd, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011; 474: 298-306.
3. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369: 1641-1657.
4. Saxena A, Kaur K, Hegde S, Kalekhan FM, Baliga MS, Fayad R. Dietary agents and phytochemicals in the prevention and treatment of experimental ulcerative colitis. J Tradit Complement Med. 2014; 4: 203-217.
5. Clapper ML, Cooper HS, Chang WC. Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta Pharmacol Sin. 2007; 28: 1450-1459.
6. Runtsch MC, Hu R, Alexander M, Wallace J, Kagele D, Petersen C, Valentine JF, Welker NC, Bronner MP, Chen X, Smith DP, Ajami NJ, Petrosino JF, et al. MicroRNA- 146a constrains multiple parameters of intestinal immunity and increases susceptibility to DSS colitis. Oncotarget. 2015; 6: 28556-28572. doi: 10.18632/oncotarget.5597.
7. Ng SC, Tang W, Leong RW, Chen M, Ko Y, Studd C, Niewiadomski O, Bell S, Kamm MA, de Silva HJ, Kasturiratne A, Senanayake YU, Ooi CJ, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut. 2015; 64: 1063-1071.
8. Williamson G, Dionisi F, Renouf M. Flavanols from green tea and phenolic acids from coffee: critical quantitative evaluation of the pharmacokinetic data in humans after consumption of single doses of beverages. Mol Nutr Food Res. 2011; 55: 864-873.
9. Touaibia M, Jean-Francois J, Doiron J. Caffeic Acid, a versatile pharmacophore: an overview. Mini Rev Med Chem. 2011; 11: 695-713.
10. Ye Z, Liu Z, Henderson A, Lee K, Hostetter J, Wannemuehler M, Hendrich S. Increased CYP4B1 mRNA is associated with the inhibition of dextran sulfate sodiuminduced colitis by caffeic acid in mice. Exp Biol Med (Maywood). 2009; 234: 605-616.
11. Ananthakrishnan AN. Environmental Risk Factors for Inflammatory Bowel Diseases: A Review. Dig Dis Sci. 2015; 60: 290-298.
12. Derrien M, Collado MC, Ben-Amor K, Salminen S, de Vos WM. The Mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Appl Environ Microbiol. 2008; 74: 1646-1648.
13. Derrien M, Belzer C, de Vos WM. Akkermansia muciniphila and its role in regulating host functions. Microb Pathog. 2016. DOI: 10.1016/j.micpath.2016.02.005.
14. Roopchand DE, Carmody RN, Kuhn P, Moskal K, Rojas- Silva P, Turnbaugh PJ, Raskin I. Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome. Diabetes. 2015; 64: 2847-2858.
15. Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin LS, Centola M, Li X. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis. 2009; 15: 341- 352.
16. Hakansson A, Tormo-Badia N, Baridi A, Xu J, Molin G, Hagslatt ML, Karlsson C, Jeppsson B, Cilio CM, Ahrne S. Immunological alteration and changes of gut microbiota after dextran sulfate sodium (DSS) administration in mice. Clin Exp Med. 2015; 15: 107-120.
17. Han F, Zhang H, Xia X, Xiong H, Song D, Zong X, Wang Y. Porcine beta-defensin 2 attenuates inflammation and mucosal lesions in dextran sodium sulfate-induced colitis. J Immunol. 2015; 194: 1882-1893.
18. Tsai HF, Wu CS, Chen YL, Liao HJ, Chyuan IT, Hsu PN. Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis. J Mol Med (Berl). 2015. DOI: 10.1007/s00109-015-1368-x.
19. McGuckin MA, Eri R, Simms LA, Florin TH, Radford- Smith G. Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm Bowel Dis. 2009; 15: 100-113.
20. Bento AF, Leite DF, Claudino RF, Hara DB, Leal PC, Calixto JB. The selective nonpeptide CXCR2 antagonist SB225002 ameliorates acute experimental colitis in mice. J Leukoc Biol. 2008; 84: 1213-1221.
21. Banoth B, Chatterjee B, Vijayaragavan B, Prasad MV, Roy P, Basak S. Stimulus-selective crosstalk via the NF-kappaB signaling system reinforces innate immune response to alleviate gut infection. Elife. 2015; 4. DOI: 10.7554/ eLife.05648.
22. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med. 2008; 263: 591- 596.
23. Du C, Wang P, Yu Y, Chen F, Liu J, Li Y. Gadolinium chloride improves the course of TNBS and DSS-induced colitis through protecting against colonic mucosal inflammation. Sci Rep. 2014; 4: 6096.
24. Bufalo MC, Ferreira I, Costa G, Francisco V, Liberal J, Cruz MT, Lopes MC, Batista MT, Sforcin JM. Propolis and its constituent caffeic acid suppress LPS-stimulated pro-inflammatory response by blocking NF-kappaB and MAPK activation in macrophages. J Ethnopharmacol. 2013; 149: 84-92.
25. Ferreira CM, Vieira AT, Vinolo MA, Oliveira FA, Curi R, Martins Fdos S. The central role of the gut microbiota in chronic inflammatory diseases. J Immunol Res. 2014; 2014: 689492.
26. Mar JS, Nagalingam NA, Song Y, Onizawa M, Lee JW, Lynch SV. Amelioration of DSS-induced murine colitis by VSL#3 supplementation is primarily associated with changes in ileal microbiota composition. Gut Microbes. 2014; 5: 494-503.
27. Duenas M, Munoz-Gonzalez I, Cueva C, Jimenez-Giron A, Sanchez-Patan F, Santos-Buelga C, Moreno-Arribas MV, Bartolome B. A survey of modulation of gut microbiota by dietary polyphenols. Biomed Res Int. 2015; 2015: 850902.
28. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol. 2004; 54: 1469-1476.
29. Png CW, Linden SK, Gilshenan KS, Zoetendal EG, McSweeney CS, Sly LI, McGuckin MA, Florin TH. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. 2010; 105: 2420-2428.
30. Rajilic-Stojanovic M, Shanahan F, Guarner F, de Vos WM. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis. 2013; 19: 481-488.
31. Kang CS, Ban M, Choi EJ, Moon HG, Jeon JS, Kim DK, Park SK, Jeon SG, Roh TY, Myung SJ, Gho YS, Kim JG, Kim YK. Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PLoS One. 2013; 8: e76520.
32. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013; 110: 9066-9071.
33. Anhe FF, Pilon G, Roy D, Desjardins Y, Levy E, Marette A. Triggering Akkermansia with dietary polyphenols: a new weapon to combat the metabolic syndrome? Gut Microbes. 2016; 7: 146-153.
34. Axling U, Olsson C, Xu J, Fernandez C, Larsson S, Strom K, Ahrne S, Holm C, Molin G, Berger K. Green tea powder and Lactobacillus plantarum affect gut microbiota, lipid metabolism and inflammation in high-fat fed C57BL/6J mice. Nutr Metab (Lond). 2012; 9: 105.
35. Cox LM, Blaser MJ. Pathways in microbe-induced obesity. Cell Metab. 2013; 17: 883-894.
36. Pinho E, Soares G, Henriques M. Evaluation of antibacterial activity of caffeic acid encapsulated by beta-cyclodextrins. J Microencapsul. 2015; 32: 804-810.
37. Zhao J, Zhang Z, Dai J, wang L, Zhang C, Ye Y, Li L. Synergistic protective effect of chlorogenic acid, apigenin and caffeic acid against carbon tetrachloride-induced hepatotoxicity in male mice. RSC Adv. 2014; 4: 43057- 43063.
38. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69: 238-249.
39. Zhang Z, Lu H, Huan F, Meghan C, Yang X, Wang Y, Wang X, Wang X, Wang SL. Cytochrome P450 2A13 mediates the neoplastic transformation of human bronchial epithelial cells at a low concentration of aflatoxin B1. Int J Cancer. 2014; 134: 1539-1548.
40. Håkansson Å, Tormo-Badia N, Baridi A, Xu J, Molin G, Hagslätt ML, Karlsson C, Jeppsson B, Cilio CM, Ahrné S. Immunological alteration and changes of gut microbiota after dextran sulfate sodium (DSS) administration in mice. Clin Exp Med. 2015; 15: 107-120.